If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Correspondence: Alexander Egeberg, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, 2900 Hellerup, Denmark.
In psoriasis patients, incidence rates of Crohn disease (CD) and ulcerative colitis (UC) have been increased in epidemiological studies and certain clinical trials, yet the association remains poorly understood. We studied a 20-year nationwide cohort of 235,038 Danish adults with psoriasis and a 1:1 matched reference group. Less than 1% of psoriasis patients developed CD or UC during follow-up. Incidence rates of CD were highest for younger women with psoriasis and patients with concurrent psoriatic arthritis, whereas men with psoriasis had particularly high incidence rates of UC compared with their non-psoriasis peers. Adjusted hazard ratios of CD were 1.84 (95% confidence interval [CI]= 1.47–2.29) and 2.38 (95% CI = 1.62–3.49) among psoriasis patients treated with topical and systemic nonbiologic therapy, respectively. No definite CD cases occurred during biologic therapy. For UC, adjusted hazard ratios were 1.49 (95% CI = 1.29–1.72), 1.51 (95% CI = 1.14–2.01), and 1.23 (95% CI = 0.39–3.86, P = 0.7197) for psoriasis patients receiving topical, systemic nonbiologic, and biologic therapy, respectively. Time to CD (but not UC) diagnosis was significantly longer for psoriasis patients compared with the general population, and patients receiving systemic treatment had the longest time to CD and UC. Psoriasis was associated with increased risk of CD and UC. Particular risk factors included sex and psoriatic arthritis.
Psoriasis is a common chronic inflammatory skin disease characterized by T helper cell infiltrates, predominately with T helper type 1 and T helper type 17 cells, and expression of IL-17, IL-23, and TNF-α. Clinically, psoriasis is characterized by either widespread or localized sharply demarcated silvery, scaly, and erythematous plaques distributed symmetrically.
Epidemiological studies have established strong associations between psoriasis and Crohn disease (CD) and ulcerative colitis (UC), with increased risk of CD and UC in patients with psoriasis and vice versa (
). CD and UC represent the two forms of inflammatory bowel disease (IBD) and are believed to occur as a host response to intestinal microbes in genetically predisposed individuals (
In recent years, significant advances have been made in the understanding and treatment of both psoriasis and IBD, and shared inflammatory pathways have enabled simultaneous treatment of both diseases with biologics targeting TNF-α and IL-12/23. However, although biologics inhibiting the IL-17 pathway have been shown to be efficacious for treatment of psoriasis and psoriatic arthritis (PsA) (
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials.
Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.
Data on incidence rates (IRs) of CD and UC among psoriasis patients in clinical trials have been conflicting and are difficult to compare with IRs from observational studies, because patient characteristics and diagnostic methods often differ considerably. The aims of this nationwide study was to examine the incidence and risk of CD and UC in patients with psoriasis treated with topical, systemic nonbiologic, and biologic therapy and to provide strata-specific data on the IBD.
Results
The study cohort comprised a total of 235,038 patients with psoriasis and 235,038 matched non-psoriasis individuals from the general population, all without a history of CD or UC at baseline. Among patients receiving topical treatment or systemic nonbiologic therapy and the general population, there was a slight female predominance, whereas the majority of biologics-treated patients were men (Table 1). The mean age at baseline was lower among patients who received treatment with biologics during the study compared with psoriasis patients receiving topical or systemic nonbiologic therapy. A positive family history (in a first-degree relative) of IBD was slightly more frequent among patients with psoriasis, with comparable estimates among those patients receiving topical, systemic nonbiologic, and biologic therapy. Patients with psoriasis had a higher prevalence of smoking, alcohol abuse, and medical comorbidity compared with the general population (Table 1).
Table 1Characteristics of the the study population
During the study period, a total of 257/464/664 and 124/252/383 cases of definite/probable/possible CD occurred among patients with psoriasis and the general population, respectively (Figure 1 and Table 2). The IR (per 10,000 person-years) of definite CD was 1.55 (95% confidence interval [CI] = 1.37–1.76) among patients with psoriasis and 0.79 (95% CI = 0.67–0.95) in the age- and sex-matched general population. Stratified by psoriasis treatment, the IRs of definite CD were 1.96 (95% CI = 1.40–2.75) among those receiving systemic nonbiologic therapy and 1.51 (95% CI = 1.32–1.73) among patients receiving topical treatment. The IRs of definite/probable/possible CD among psoriasis patients with and without concurrent PsA are presented in Supplementary Table S1 online. Incidence of CD decreased with increasing age (see Supplementary Table S2 online). After adjustment for potential confounding factors, psoriasis was significantly associated with increased risk of definite CD (adjusted hazard ratio [aHR] = 1.88, 95% CI = 1.51–2.34), probable CD (aHR = 1.74, 95% CI = 1.49–2.03), and possible CD (aHR = 1.63, 95% CI = 1.44–1.85), respectively. Although the risk of CD was increased in patients receiving topical and systemic nonbiologic treatment, the aHR of CD was not significantly increased in patients treated with biologic therapy, regardless of presence or absence of PsA (Table 3), although the sample size of patients treated with biologics was much smaller than the other treatment modalities. Limiting analyses of PsA to patients for whom the diagnosis had been verified by a rheumatologist, the aHR of CD was 2.90 (95% CI = 1.61–5.22).
Figure 1Prevalence of inflammatory bowel disease (IBD) in patients with psoriasis. Percentage of patients developing new-onset Crohn disease (CD) and ulcerative colitis (UC) during follow-up.
Table 3HRs of the risk of Crohn disease in patients with psoriasis compared with the general population
Psoriasis Type
Definite CD
Probable CD
Possible CD
Adjusted HR
95% CI
P-Value
Adjusted HR
95% CI
P-Value
Adjusted HR
95% CI
P-Value
Any psoriasis
1.88
1.51–2.34
<0.0001
1.74
1.49–2.03
<0.0001
1.63
1.44–1.85
<0.0001
Topical treatment
1.84
1.47–2.29
<0.0001
1.72
1.47–2.02
<0.0001
1.62
1.42–1.84
<0.0001
Systemic nonbiologic treatment
2.38
1.62–3.49
<0.0001
1.92
1.43–2.58
<0.0001
1.74
1.36–2.23
<0.0001
Biologic treatment
Not applicable
0.56
0.08–4.00
0.5622
1.20
0.38–3.75
0.7561
Psoriasis without PsA
1.83
1.47–2.27
<0.0001
1.70
1.46–1.99
<0.0001
1.59
1.40–1.81
<0.0001
Topical treatment
1.81
1.45–2.27
<0.0001
1.70
1.45–2.00
<0.0001
1.59
1.39–1.81
<0.0001
Systemic nonbiologic treatment
2.08
1.34–3.23
<0.0001
1.76
1.26–2.45
0.0009
1.65
1.25–2.17
0.0004
Biologic treatment
Not applicable
0.88
0.12–6.31
0.9004
1.87
0.60–5.85
0.2821
Psoriasis with PsA
3.10
1.90–5.06
<0.0001
2.39
1.63–3.50
<0.0001
2.28
1.67–3.11
<0.0001
Topical treatment
2.63
1.37–5.07
<0.0001
2.28
1.40–3.71
0.0009
2.40
1.65–3.51
<0.0001
Systemic nonbiologic treatment
4.11
2.13–7.93
<0.0001
2.79
1.61–4.82
0.0002
2.29
1.42–3.70
0.0007
Biologic treatment
Not applicable
Not applicable
Not applicable
Adjusted for age, sex, socioeconomic status, smoking, and alcohol abuse. Bold text indicates “all psoriasis patients” regardless of whether they receive topical, systemic nonbiologic, or biologic therapy.
During the study period, 504/870/1274 and 325/546/778 patients with psoriasis and general population referents, respectively, developed definite/probable/possible UC. The incidence of definite UC was 3.17 (95% CI = 2.90–3.46) among patients with psoriasis and 2.08 (95% CI = 1.87–2.32) in the general population. Comparable IRs were seen among patients receiving topical and systemic nonbiologic therapy, whereas lower IRs (although with wide and overlapping CIs) were seen for psoriasis treated with biologics (Table 2). The IRs in different age groups are presented in Supplementary Table S3 online. In adjusted models, there was a significantly increased risk of UC in patients with psoriasis (definite UC: aHR = 1.49, 95% CI = 1.30–1.71), although the risk of definite UC reached statistical significance only in patients without PsA (aHR = 1.50, 95% CI = 1.30–1.73) but not in patients with concurrent PsA (aHR = 1.29, 95% CI = 0.85–1.98, P = 0.2341) (Table 4). Among psoriasis patients with rheumatologist-verified PsA, the aHR of UC was 1.22 (95% CI = 0.80–1.87, P = 0.3589).
Table 4HRs of the risk of ulcerative colitis in patients with psoriasis compared with the general population
Definite UC
Probable UC
Possible UC
Adjusted HR
95% CI
P-Value
Adjusted HR
95% CI
P-Value
Adjusted HR
95% CI
P-Value
Any psoriasis
1.49
1.30–1.71
<0.0001
1.52
1.37–1.70
<0.0001
1.56
1.43–1.71
<0.0001
Topical treatment
1.49
1.29–1.72
<0.0001
1.52
1.36–1.70
<0.0001
1.55
1.42–1.70
<0.0001
Systemic nonbiologic treatment
1.51
1.14–2.01
0.0041
1.54
1.24–1.92
<0.0001
1.65
1.38–1.97
<0.0001
Biologic treatment
1.23
0.39–3.86
0.7197
1.85
0.84–4.16
0.1356
1.13
0.47–2.74
0.7816
Psoriasis without PsA
1.50
1.30–1.73
<0.0001
1.51
1.35–1.68
<0.0001
1.53
1.39–1.67
<0.0001
Topical treatment
1.49
1.29–1.72
<0.0001
1.50
1.34–1.67
<0.0001
1.52
1.39–1.67
<0.0001
Systemic nonbiologic treatment
1.67
1.24–2.25
0.0007
1.58
1.25–2.00
0.0001
1.59
1.31–1.94
<0.0001
Biologic treatment
1.23
0.31–4.97
0.7684
1.83
0.68–4.91
0.2307
1.36
0.51–3.65
0.5370
Psoriasis with PsA
1.29
0.85–1.98
0.2341
1.81
1.35–2.42
<0.0001
2.21
1.77–2.77
<0.0001
Topical treatment
1.58
0.97–2.59
0.0685
2.06
1.45–2.91
<0.0001
2.42
1.85–3.18
<0.0001
Systemic nonbiologic treatment
0.85
0.38–1.92
0.6962
1.39
0.83–2.33
0.2115
1.99
1.38–2.88
0.0003
Biologic treatment
1.29
0.18–9.30
0.8010
2.09
0.62–4.50
0.3008
0.77
0.11–5.52
0.7968
Adjusted for age, sex, socioeconomic status, smoking, and alcohol abuse. Bold text indicates “all psoriasis patients” regardless of whether they receive topical, systemic nonbiologic, or biologic therapy.
Uses of different systemic nonbiologic and biologic therapies are presented in Supplementary Table S4 online. Among patients with definite IBD, the UC-to-CD ratio was 2.8 in the general population and 2.3 in patients with psoriasis (P = 0.105). The highest age-specific IR estimate (per 10,000 person-years) of CD was in women with psoriasis younger than 30 years (IR estimate = 4.28, 95% CI = 3.14–5.83), whereas the highest IR estimate of UC was seen in men with psoriasis aged 30–40 years (IR estimate = 5.13; 95% CI = 3.36–6.81) (Figure 2a and b). Surprisingly, mean time to diagnosis of CD, but not UC, was significantly longer among patients with psoriasis, compared with the general population, even among patients receiving only topical therapy (see Supplementary Table S5 online). However, for patients receiving systemic nonbiologic and especially biologic therapy, time to CD and UC diagnosis was significantly longer than the general population. Among patients with definite IBD, 66.6% of CD patients and 75.8% of UC patients had data specifying anatomical location, whereas the remaining patients were recorded as “unspecified” (International Classification of Diseases, 10th revision [ICD-10] codes K50.9 and K51.9, respectively). Although there were some numerical differences in anatomical involvement of CD or UC among patients with psoriasis and the general population, none of these differences were statistically significant (Table 5). Among patients developing definite CD, 9.8% (psoriasis) and 16.5% (general population) had a family history of either CD or UC (P = 0.127), whereas a positive family history was seen in 7.0% (psoriasis) and 8.2% (general population) of individuals who developed definite UC during the study, respectively (P = 0.612). Using patients without psoriasis as a reference, risk of CD, but not UC, was higher among patients with longer psoriasis duration (see Supplementary Table S6 online). Sensitivity analyses with additional adjustment for use of nonsteroidal anti-inflammatory drugs, systemic antibiotics, and oral contraceptives yielded similar findings compared with our primary analyses (see Supplementary Table S7 online). Furthermore, use of a different reference population where non-psoriasis individuals were required to have been seen in the Danish health care system within 30 days on the corresponding psoriasis patients index date did not significantly alter the findings of our primary analyses (see Supplementary Table S8 online).
Figure 2Age-specific incidence of Crohn disease and ulcerative colitis in men and women with psoriasis and in the general population. (a) Incidence of definite Crohn disease by sex and age in the general population and patients with psoriasis. (b) Incidence of definite ulcerative colitis by sex and age in the general population and patients with psoriasis. ∗Significantly higher for women with psoriasis compared with women without psoriasis. ǂSignificantly higher for men with psoriasis compared with men without psoriasis. IR, incidence rate; y, year.
In this nationwide cohort study spanning two decades, we found a significantly increased risk of CD and UC among patients with psoriasis. No differences were seen in anatomical IBD location between psoriasis patients and the general population. Higher CD (but not UC) risk was seen with longer psoriasis duration.
In line with our findings, a previous Danish study found a positive association between psoriasis and risk of CD and UC, although IBD was not limited to diagnoses made by gastroenterologists (
). Moreover, that study pooled together use of certain systemic nonbiologic and biologic therapies (i.e., retinoids, psoralens, etanercept, and ustekinumab) but did not assess the relationship with a number of other frequently used treatment modalities (including methotrexate, cyclosporine, apremilast, infliximab, adalimumab, and secukinumab). This study therefore expands the existing literature considerably, not only by using more rigorous criteria for IBD (definite/probable/possible) but also by showing specific risk estimates among patients receiving topical therapy (mild psoriasis), systemic nonbiologic therapy (moderate to severe psoriasis), biologic treatment (most severe psoriasis). However, only relatively few patients (n = 2,187) were treated with biologics, thereby limiting interpretation of IBD risk in these patients. Since their introduction, adalimumab and ustekinumab have been the most frequently used biologics for psoriasis in Denmark (
), which may explain the lack of association with IBD in the biologics-treated cohort, because these drugs may also dampen symptoms of IBD. Consequently, patients receiving biologic treatment of their psoriasis would experience fewer IBD symptoms and would therefore be less likely to be diagnosed with IBD. On the other hand, because studies have reported that multiple sclerosis is less severe in patients with concomitant IBD (
), and it is tempting to speculate that milder psoriasis may indeed be more strongly associated with IBD as well. Indeed, one previous study reported that patients with psoriasis and concurrent IBD had a milder psoriasis phenotype compared with psoriasis patients without IBD, whereas patients with CD and concurrent psoriasis had more severe CD compared with patients without psoriasis (
). Along these lines, it is well-established that although psoriasis is slightly more frequent in women, women tend to have milder psoriasis than men (
Severity of psoriasis differs between men and women: a study of the clinical outcome measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register patients.
). In our study, there were striking sex differences, for example, a noticeably higher incidence of CD among women with psoriasis (Figure 2). Female sex is also a risk factor for complications such as colectomy among IBD patients (
), highlighting the importance of these observed sex differences. Although psoriasis patients tend to smoke more than the general population, smoking may aggravate CD while having beneficial effects on UC (
). The high increased risk of CD and UC among psoriasis patients with concurrent PsA may, at least in part, be explained by shared genetic risk loci such as IL12B, 5q31, IL23R, and IL2/IL21 (
In their respective clinical development programs, the incidence of IBD among patients treated with IL-17 inhibitors has been conspicuously higher than what we observed in our psoriasis population. Between-study comparison of IRs may be challenging, because different diagnostic methods may be applied. For example, during the ixekizumab clinical trial program, adjudication was performed using the methodology applied in the well-established Registre Epidemiologique des Maladies de l’Appareil Digestif (EPIMAD) registry (
Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.
, pp 89). Nonetheless, from their clinical development programs, it was reported that IRs (shown here per 10,000 person-years) of CD were 11 (95% CI = 5–23) for ixekizumab (
Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials.
Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.
Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials.
Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.
). However, although the incidence of CD and UC may be increased with use of antibodies targeting IL-17, the absolute risk associated with these drugs remains low. Although the exact reason for the increased risk remains unclear, inhibition of IL-17 has been shown to weaken the intestinal epithelial barrier, thereby leading to increased gastrointestinal inflammation (
). Although this study may help put these clinical trial data into context, we emphasize that this study was not aimed at assessing IBD risk associated with specific drugs.
Several strengths and limitations of this study warrant discussion. Exclusion of confirmed or suspected IBD before the study start enabled a more direct comparison with IRs observed in clinical trials, whereas the inclusion of probable IBD diagnoses enabled comparison with clinical trials in which potential IBD cases that cannot definitively be confirmed to be either CD or UC were included. Moreover, possible IBD may include patients with unspecific gastrointestinal symptoms that may constitute irritable bowel syndrome or other gastroenterological conditions that do not meet the formal diagnostic criteria of CD or UC and may be a more realistic representation of the gastrointestinal complaints that patients report, for example, when consulting a dermatologist. However, although we defined cases of definite CD and UC as patients for whom the diagnosis was ascertained by a gastroenterologist, we lacked information on the specific diagnostic criteria on which the diagnosis was based, including data such as endoscopy findings and gastrointestinal histology samples. Moreover, in the psoriasis clinical trial program for ixekizumab, adjudication was performed in accordance with the EPIMAD definition, whereas our IBD cases were not, and although our IRs may be more appropriate for direct comparison with those from clinical trials, these definitory differences should be kept in mind when interpreting our findings. Furthermore, description of family history of IBD was limited by the fact that information on true biological relatives is not always recorded, for example, in cases of adoption or migration. Finally, we had approximately 8,100 person-years of exposure to biologics during our study (of which 76.4 person-years were for secukinumab), which may limit interpretability of our findings in the biologics-treated group, and especially with regard to IBD risk in patients receiving anti-IL-17 therapy.
In conclusion, we found an increased risk of CD and UC in patients with psoriasis. Patients with concurrent PsA had the highest risk of CD but not UC. Female sex and PsA were noticeable risk factors for IBD. Patients receiving biologic therapy for psoriasis did not have an increased IBD risk compared with the general population, likely because many anti-psoriatic biologics (e.g., adalimumab, infliximab, and ustekinumab) are also effective in treating symptoms of IBD, thereby postponing time to diagnosis. Although timely referral may be appropriate in patients presenting with gastrointestinal complaints consistent with IBD, the absolute psoriasis-associated risk of CD and UC remains low.
Materials and Methods
Study approval was obtained from the Danish Data Protection Agency. Register studies do not require ethical approval in Denmark.
Data sources and study population
Routinely collected administrative and health care data in Denmark can be linked at the individual level for research purposes using the unique identification number assigned to all residents at birth or migration (
). The tax-supported health care system provides unencumbered access to health care, including general practitioners and hospitals, for all Danish residents. All hospital admissions and outpatient consultations are recorded in the Danish National Patient Register according to the Danish modification of the ICD-10 (
). Drugs given during hospital admission, or dispensed from hospital clinics (e.g., biologic therapy) are also recorded in this register, whereas all prescriptions dispensed from pharmacies are registered in the Danish Registry of Medicinal Products Statistics (
Egeberg A, Thyssen JP, Wu JJ, Skov L. Risk of first-time and recurrent depression in patients with psoriasis—a population-based cohort study [e-pub ahead of print]. Br J Dermatol 2018b. https://doi.org/10.1111/bjd.17208.
From a source population comprising all Danish adults (≥18 years) between January 1, 1997, and December 31, 2016, we identified all patients with recorded codes consistent with psoriasis, as previously described (
Egeberg A, Thyssen JP, Wu JJ, Skov L. Risk of first-time and recurrent depression in patients with psoriasis—a population-based cohort study [e-pub ahead of print]. Br J Dermatol 2018b. https://doi.org/10.1111/bjd.17208.
). The study start for patients was the date of first recorded occurrence of psoriasis or their 18th birthday, whichever came last. Patients were followed up until the first of either December 31, 2016; death; migration; or the occurrence of an endpoint. Patient were matched (birth date and sex) with general population individuals in a 1:1 ratio. The index date (study start date) for the matched individuals was the same as for the corresponding psoriasis patients. To ensure that we captured only new-onset IBD during follow-up, study subjects were excluded if they had received a diagnosis of either confirmed or suspected IBD any time before the index date. The Strengthening the Reporting of Observational Studies in Epidemiology recommendations were used for conduct and reporting of this study (
The co-primary IBD endpoints were a first-time diagnosis of CD (ICD-10 K50) or UC (ICD-10 K51). The IBD diagnosis was categorized into definite IBD, probable IBD, and possible IBD. Definite IBD included only patients who received an IBD diagnosis (CD or UC) that was verified by a gastroenterologist and did not have any subsequent diagnosis of UC (for patients with definite CD) or CD (for patients with definite UC). Probable IBD included patients who received an IBD diagnosis either by a gastroenterologist, abdominal surgeon, or internal medicine specialist. Possible IBD included any physician diagnosis of IBD (confirmed or suspected), regardless of specialty.
Statistical analysis
Descriptive characteristics were presented as means and standard deviations for continuous variables and frequencies and as percentages for categorical variables. Patients were divided into groups and categorized according to their use of treatments prescribed specifically for treatment of their psoriasis and divided into the following groups: (i) topical or no treatment, (ii) systemic nonbiologic treatment, and (iii) biologic treatment. Topical treatment included topical corticosteroids and/or topical vitamin D analogs. Systemic nonbiologic treatment included methotrexate, cyclosporine, acitretin, and apremilast. Biologic treatment included adalimumab, etanercept, infliximab, ustekinumab, and secukinumab. To accurately assess the impact of psoriasis treatment, these drugs were included only if they were prescribed specifically for psoriasis. To ensure correct risk-time allocation and to explore the temporal relationship, such psoriasis therapy was included as a time-varying variable, whereby patients could contribute risk-time in the topical treatment group until they received their first systemic nonbiologic or biologic treatment (if appropriate). Similarly, patients were considered exposed in the systemic nonbiologic group only until they were switched to a biologic, at which time they would contribute risk-time in the biologics-treated group. We presented IRs per 10,000 person-years of exposure and calculated aHRs (in which age, sex, socioeconomic status, smoking, and alcohol abuse were considered) through Cox regression models. Socioeconomic status was calculated as an age-standardized index (quintiles) based on the mean annual household income in the last 5 years before the study start. IRs and HRs were presented overall and in strata based on presence or absence of PsA and in age bands. We performed sensitivity analyses with additional adjustment for use of nonsteroidal anti-inflammatory drugs, systemic antibiotics, and oral contraceptives. To ensure that our findings were not solely explained by differences in health care use, we also performed a sensitivity analysis in which the reference population was sampled from people without psoriasis who were seen in the Danish health care system within 30 days of the index date for the respective psoriasis patients. Model assumptions, including the absence of interactions between model covariates, were tested and found to be valid unless otherwise specified. All statistical tests were conducted using a level of significance of 0.05, and results were reported with 95% confidence intervals (CIs), where applicable. All analyses were performed using SAS statistical software, version 9.4 (SAS Institute, Cary, NC) and STATA software, version 13.0 (StataCorp, College Station, TX).
Conflict of Interest
Outside of the submitted work, AE has received research funding from Pfizer, Eli Lilly, the Danish National Psoriasis Foundation, and the Kgl Hofbundtmager Aage Bang Foundation and honoraria as a consultant and/or speaker from Almirall; Leo Pharma; Samsung Bioepis Co., Ltd.; Pfizer; Eli Lilly; Novartis; Galderma; and Janssen Pharmaceuticals. Outside of the submitted work, JPT is supported by an unrestricted grant from the Lundbeck Foundation and has received speaker honoraria from Galderma, Sanofi-Genzyme, LEO Pharma, and MEDA; has attended advisory board meetings for Roche, Eli Lilly, and Sanofi-Genzyme; and is an investigator for LEO Pharma and Eli Lilly. Outside of the submitted work, JB reports personal fees from AbbVie, Janssen-Cilag, Celgene, MSD, Pfizer, and Takeda and nonfinancial support from Calpro. Outside of the submitted work, J-FC has served as a consultant or advisory board member for Abbvie, Amgen, Boehringer-Ingelheim, Celgene Corporation, Celltrion, Enterome, Ferring, Genentech, Janssen and Janssen, Eli Lilly, Medimmune, Merck & Co., Pfizer, Protagonist, Second Genome, Seres, Shire, Takeda, and Theradiag; has been a speaker for Abbvie and Ferring; has been a member of the speaker’s bureau for Amgen; and has stock options with Intestinal Biotech Development and Genfit.
Author Contributions
AE had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: AE. Acquisition, analysis, and interpretation of data: all authors. Drafting of the manuscript: AE. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: AE. Obtained funding: none. Administrative, technical, or material support: AE. Study supervision: AE.
Egeberg A, Thyssen JP, Wu JJ, Skov L. Risk of first-time and recurrent depression in patients with psoriasis—a population-based cohort study [e-pub ahead of print]. Br J Dermatol 2018b. https://doi.org/10.1111/bjd.17208.
Severity of psoriasis differs between men and women: a study of the clinical outcome measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register patients.
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials.
Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.
32483-7&id=gr1.jpg){kind=link}
32483-7&id=gr2.jpg){kind=link}